Cidara Therapeutics Earnings Estimate

By analyzing Cidara Therapeutics' earnings estimates, investors can diagnose different trends across Cidara Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Cidara Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options. Cidara Therapeutics is projected to generate -6.274175 in earnings per share on the 31st of December 2024. Cidara Therapeutics earnings estimates module stress-tests analyst consensus about projected Cidara Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Cidara Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Cidara Therapeutics' earnings estimates, investors can diagnose different trends across Cidara Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Cidara Therapeutics' Gross Profit is fairly stable compared to the past year. Gross Profit Margin is likely to rise to 1.02 in 2024, whereas Pretax Profit Margin is likely to drop (0.37) in 2024. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.